Clinical Trials Logo

Gender Dysphoria clinical trials

View clinical trials related to Gender Dysphoria.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05489159 Active, not recruiting - Insulin Resistance Clinical Trials

Sleep and IR in Transgender Adolescents

ATP
Start date: October 12, 2022
Phase:
Study type: Observational

Disordered sleep is a health issue with significant impacts on physical and psychological well-being that has increased in prevalence, but its impact on transgender adolescents has not been fully quantified. While there is found to be an impact of sex steroids on sleep, and sex-dependent differences in the impact of sleep duration and quality on insulin resistance (IR), there is limited available information regarding the impact of Gender Affirming Hormone Therapy (GAHT) for transgender individuals on sleep and IR. Our study aims to quantify the impacts of GAHT on sleep and IR in the pediatric transgender population as well as determine the degree of correlation of sleep to IR in this population.

NCT ID: NCT04573127 Active, not recruiting - Gender Dysphoria Clinical Trials

Gender Dysphoria: Epidemiological Data

DyGenEpi
Start date: July 27, 2020
Phase:
Study type: Observational

Retrospective study in a single academic regional transgender referral center. data from the cohort follow-up in CHRU de Nancy

NCT ID: NCT04554849 Active, not recruiting - Gender Dysphoria Clinical Trials

Demographic Characteristics and Psychosocial Health of Transgender People

DyGeDem
Start date: July 24, 2020
Phase:
Study type: Observational

To study demographic characteristics of subjects referred to endocrine care for gender dysphoria and their psychosocial health

NCT ID: NCT04508231 Active, not recruiting - Gender Dysphoria Clinical Trials

Metabolic Consequences of Cross-sex Hormonal Treatment

DysGeMet
Start date: July 24, 2020
Phase:
Study type: Observational

Retrospective study in a single academic regional transgender referral center. Analyse VAT, body composition and metabolic parameters in non-obese transgender subjects one year after starting gender-affirming hormone therapy and in controls